MLKL-IN-6

Overview

MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL). MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects.

Application

Products | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Obesity | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Mixed Lineage Kinase | Products > Signaling Pathways > Necroptosis

Product Information

• Catalog No.: HY-156119
• CAS No.: 3080148-24-6
• Molecular Formula: C20H18N4O5
• Molecular Weight: 394.38
• Purity: 98.57%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (12.68 mM); Clear solution
• Availability: In-stock

Source

Original product source